Hostname: page-component-586b7cd67f-dlnhk Total loading time: 0 Render date: 2024-11-29T03:43:50.252Z Has data issue: false hasContentIssue false
  • English
  • Français

Recent Case Developments

Published online by Cambridge University Press:  06 January 2021

Lewis Osterman
Get access Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Notes and Comments
Information
American Journal of Law & Medicine , Volume 41 , Issue 4 , November 2015 , pp. 688 - 691
Copyright
Copyright © American Society of Law, Medicine and Ethics and Boston University 2015

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1 Amarin Pharma, Inc. v. U.S. Food & Drug Admin., No. 1.15-cv-3588-PAE, 2015 WL 4720039 (S.D.N.Y. Aug. 7, 2015).

2 See id.

3 Complaint at 69-70, Amarin Pharma, 2015 WL 4720039 (No. 1.15-cv-3588-PAE).

4 Amarin Pharma 2015 WL 4720039, at *49.

5 See id. at 67.

6 Complaint, supra note 3, at 3.

7 Id. at 3 n.4.

8 Id. at 3.

9 Id. at 3 n.4.

10 See id. at 4.

11 Id. at 4.

12 Memorandum of Law in Opposition to Plaintiffs' Motion for Preliminary Injunction at 5, Amarin Pharma, Inc. v. U.S. Food & Drug Admin., 2015 WL 4720039 (S.D.N.Y. Aug. 7, 2015) (No. 1:15-CV-3588-PAE) [hereinafter FDA Memo].

13 Id. at 3.

14 See Complaint, supra note 3, at 19.

15 See id. at 19-20.

16 See id. at 23.

17 See id. at 3; FDA Memo, supra note 12, at 5.

18 Id. at 5.

19 Complaint, supra note 3, at 24; FDA Memo, supra note 12, at 6.

20 See FDA Memo, supra note 12, at 6.

21 Complaint, supra note 3, at 4; see FDA Memo, supra note 12, at 6.

22 Complaint, supra note 3 at 6.

23 Id. at 28.

24 See Amarin Pharma, Inc. v. U.S. Food & Drug Admin., No. 1.15-cv-3588-PAE, 2015 WL 4720039, at *2 (S.D.N.Y. Aug. 7, 2015).

25 Id. at *1.

26 See id. at *17; United States v. Caronia, 703 F.3d 149, 149 (2d Cir. 2012).

27 Caronia, 703 F.3d at 163.

28 See id.; Sorrell v. IMS Health Inc., 131 S. Ct. 2653, 2662-64 (2011).

29 Caronia, 703 F.3d at 164.

30 See Cent. Hudson Gas & Elec. Corp. v. Pub. Serv. Comm'n of N.Y., 447 U.S. 557, 566 (1980).

31 See Caronia, 703 F.3d at 168.

32 Id. (quoting Bd. of Tr. of State Univ. of N.Y. v. Fox, 492 U.S. 469, 480 (1989)).

33 Id.

34 Amarin Pharma, Inc. v. U.S. Food & Drug Admin., No. 1.15-cv-3588-PAE, 2015 WL 4720039, at *18 (S.D.N.Y. Aug. 7, 2015).

35 Id. at 47.

36 Id. at 45 (emphasis in original).

37 Id. at 49.

38 See id. at 52-53.

39 Id. at 66.

40 See id.

41 Id. at 66-67.

42 See id. at 66.

43 Id. at 67 (quoting N.Y. Progress and Prot. PAC v. Walsh, 733 F.3d 483, 488 (2d Cir. 2013)).

44 See id.

45 Id.

46 Id.

47 Id. at 67-68.

48 See Order, Amarin Pharma, Inc. v. U.S. Food & Drug Admin. 2015 WL 4720039 (S.D.N.Y. Aug. 7, 2015) (No. 1:15-cv-03588-PAE).

49 Letter to Stay Proceedings, Amarin Pharma, 2015 WL 4720039 (No. 1:15-cv-03588-PAE).

50 See id.

51 See Complaint for Declaratory and Injunctive Relief at 65-66, Pacira Pharm., Inc. v. U.S. Food & Drug Admin., 2015 WL 5256628 (S.D.N.Y Sept. 8, 2015) (No. 1:15-cv-07055-RA).

52 Id. at 72.